Product analysis
Lithium Orotate 5 mg offers a simple, clearly labeled formula at a competitive serving cost. Mood benefits remain uncertain because findings for prescription lithium do not establish the effects of this supplement.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality100
Lithium orotate is clearly identified and has a favorable compound form. The compound identity alone does not establish how it affects mood.
Ingredient Transparency100
The lithium amount and orotate form are both disclosed. That makes the contents straightforward to compare with other lithium supplements.
Value For Money80
The serving cost compares favorably. That describes affordability without establishing a mood benefit.
Customer Satisfaction90
Customer feedback is very favorable across thousands of ratings. The broad review base describes satisfaction, without establishing effectiveness or safety.
Product Focus82
Lithium is the sole ingredient directed at mood support. A general mood benefit from the supplemental serving remains unestablished, and prescription-lithium findings do not resolve that uncertainty.
- Format
Capsule - Container
- 60 Capsule(s)
- Per serving
- $0.18
- Customer rating
- 4.7 · 6,795 ratings
Goals
Lithium is the sole mood-directed ingredient, declared as lithium orotate. The saved findings recognize its amount and a connection to brain plasticity, but prescription-lithium findings do not establish mood benefits from this supplement exposure. The supplied information does not demonstrate a general mood effect for 5 mg of supplemental lithium per serving.
How this product is rated for Mood Support
Ingredient fit100
Goal fit
Dose adequacy
Pathways56
Depth
Breadth
Evidence82
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Lithium (Lithium Orotate) | 5 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability100
Lithium Compound Optimization
Dose, Safety & Label Transparency100
Elemental Disclosure Precision
Dosage Appropriateness
Value80
Cost Per Serving Efficiency
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.
- GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder.
- A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
- A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.